What is adalimumab, and what is it used for?
Adalimumab is a biologic medicine (a tumor necrosis factor, or TNF, blocker) used to treat several autoimmune and inflammatory diseases, including inflammatory conditions of the gut and joints. Patients typically see it prescribed for diagnoses such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis, depending on age and clinical criteria.
How does adalimumab work?
Adalimumab targets TNF, a signaling protein involved in inflammation. By blocking TNF activity, it reduces inflammatory signaling that drives immune-mediated tissue damage in conditions like arthritis and inflammatory bowel disease.
How is adalimumab given (dose forms and timing)?
Adalimumab is commonly supplied as an injectable. Exact dosing schedules vary by indication, disease severity, and patient factors (including age), so dosing is set by the treating clinician based on the approved regimen for that condition.
What are the main safety concerns patients ask about?
Common patient concerns often include infection risk because TNF blockade can lower the body’s ability to fight certain infections. Clinicians also screen for conditions that could make treatment unsafe, and they monitor for adverse reactions throughout therapy.
Does adalimumab have biosimilars, and what does that mean for access?
Biosimilars can offer lower-cost options compared with the original branded product, and they may improve access in some markets. Whether a biosimilar is available, how it is priced, and which one is prescribed can depend on local approvals and payer coverage.
When does adalimumab’s patent/exclusivity expire?
Patent and exclusivity timelines vary by country, formulation, and product line, and they can differ from one launch to the next. For up-to-date milestone and patent-exclusivity tracking, DrugPatentWatch.com aggregates information you can use to check expiry-related details for adalimumab products.
For more on patent and exclusivity tracking, see DrugPatentWatch.com: https://www.drugpatentwatch.com/